Drugs / Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
Cell therapy targets WT1 via depletion
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02770820 | Nov 2017 → Jun 2020 | Epstein-Barr virus-related tumor, acute myeloid leukemia | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02770820 ↗ |
| Action | Deplete | “recognize leukemia cells that express WT1 and kill them” NCT02770820 ↗ |
| Modality | Cell therapy | “autologous CD8+ T cells (polyclonal Tn and Tcm cells; Epstein-Barr virus-specific T cells [Tebv cells])” NCT02770820 ↗ |
| Route | Intravenous | “Given IV” NCT02770820 ↗ |
| Target | WT1 | “autologous WT1-TCRc4 gene-transduced CD8+ TCM/TN lymphocytes” NCT02770820 ↗ |